相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022
DIABETES CARE (2022)
Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis
Takayuki Yamada et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1 mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting
Matthew Capehorn et al.
DIABETES THERAPY (2021)
A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease
Lyndon Marc Evans et al.
ENDOCRINOLOGY DIABETES & METABOLISM (2021)
2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
John B. Buse et al.
DIABETOLOGIA (2020)
Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK
Pierre Johansen et al.
ADVANCES IN THERAPY (2020)
Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme
Stephen C. Bain et al.
DIABETES THERAPY (2020)
Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge
Lei Si et al.
VALUE IN HEALTH (2020)
Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs
Osamah M. Alfayez et al.
PRIMARY CARE DIABETES (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Impact of FDA-Required Cardiovascular Outcome Trials on Type 2 Diabetes Clinical Study Initiation From 2008 to 2017
Cameron M. Kieffer et al.
THERAPEUTIC INNOVATION & REGULATORY SCIENCE (2019)
Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis
Yue Fei et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Challenges and Opportunities Associated with Incorporating New Evidence of Drug-Mediated Cardioprotection in the Economic Modeling of Type 2 Diabetes: A Literature Review
Michael Willis et al.
DIABETES THERAPY (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes A Systematic Review and Meta-analysis
Sean L. Zheng et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum
William T. Cefalu et al.
DIABETES CARE (2018)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The Cardiovascular Biology of Glucagon-like Peptide-1
Daniel J. Drucker
CELL METABOLISM (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84)
M. L. Alva et al.
DIABETIC MEDICINE (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States
Mark D. Danese et al.
VALUE IN HEALTH (2015)
THE COST OF NON-SEVERE HYPOGLYCAEMIA IN EUROPE
B. Chubb et al.
VALUE IN HEALTH (2015)
What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?
Seamus Kent et al.
BMC NEPHROLOGY (2015)
Validation of the IMS CORE Diabetes Model
Phil McEwan et al.
VALUE IN HEALTH (2014)
Review of Utility Values for Economic Modeling in Type 2 Diabetes
Amelie Beaudet et al.
VALUE IN HEALTH (2014)
UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82
A. J. Hayes et al.
DIABETOLOGIA (2013)
Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries
Marc Evans et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2013)
Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Costs of managing severe hypoglycaemia in three European countries
Mette Hammer et al.
JOURNAL OF MEDICAL ECONOMICS (2009)
A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)
PM Clarke et al.
DIABETOLOGIA (2004)
The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making
AJ Palmer et al.
CURRENT MEDICAL RESEARCH AND OPINION (2004)
Validation of the CORE diabetes model against epidemiological and clinical studies
AJ Palmer et al.
CURRENT MEDICAL RESEARCH AND OPINION (2004)
GLP-1 and extra-islet effects
B Ahrén
HORMONE AND METABOLIC RESEARCH (2004)
Primary and subsequent coronary risk appraisal: New results from The Framingham Study
RB D'Agostino et al.
AMERICAN HEART JOURNAL (2000)
分享论文
